Zenocutuzumab dosage and usage

Zenocutuzumab is a bispecific monoclonal antibody that is mainly used to treat patients with non-small cell lung cancer (NSCLC) and pancreatic cancer carrying NRG1 gene fusion. When using this drug, a patient's specific dose is usually individually adjusted by the doctor based on the patient's weight, condition, and response to treatment.

Zetolizumab is usually given by intravenous infusion. The recommended starting dose is 600 mg given every 14 days. At the beginning of the treatment course, patients receive an initial infusion, with dose adjustments made based on therapeutic efficacy and tolerability. Doctors will decide whether the dosage or frequency of administration needs to be adjusted based on changes in the patient's condition and possible adverse reactions.

During the initial treatment phase, zetolizumab is usually administered every two weeks. Patients should follow the doctor's instructions during treatment and receive drug infusions on time. After several courses of treatment, the doctor may evaluate whether it is necessary to continue to adjust the dosing interval or dose based on the patient's efficacy and side effects. For example, if a patient responds well to treatment and side effects are manageable, the dosing period may be extended.

Intravenous infusion of zetolizumab needs to be performed in a professional medical environment, and the treatment process needs to be monitored by experienced medical personnel. At the initial stage of infusion, especially during the first administration, patients may experience infusion-related side effects, such as fever, chills, allergic reactions, etc. Therefore, during each infusion, doctors and caregivers closely monitor the patient's vital signs and prepare emergency measures for possible allergic reactions or other serious adverse reactions. Patients should perform drug infusion under the guidance of a doctor to ensure the safety of treatment.

Reference link: https://www.zailaboratory.com